Metastatic Extramammary Paget’s Disease: Pathogenesis and Novel Therapeutic Approach

por Fukuda, Keitaro, Funakoshi, Takeru
Publicado 2018

Corrigendum: Metastatic Extramammary Paget’s Disease: Pathogenesis and Novel Therapeutic Approach

por Fukuda, Keitaro, Funakoshi, Takeru
Publicado 2018

Updates on the Systemic Treatment of Advanced Non-melanoma Skin Cancer

por Tanese, Keiji, Nakamura, Yoshio, Hirai, Ikuko, Funakoshi, Takeru
Publicado 2019

Comparison of basophil activation test and lymphocyte transformation test as diagnostic assays for drug hypersensitivity

por Adachi, Takeya, Takahashi, Hayato, Funakoshi, Takeru, Hirai, Hiroyuki, Hashiguchi, Akihiko, Amagai, Masayuki, Nagao, Keisuke
Publicado 2014

Periostin Is a Key Niche Component for Wound Metastasis of Melanoma

por Fukuda, Keitaro, Sugihara, Eiji, Ohta, Shoichiro, Izuhara, Kenji, Funakoshi, Takeru, Amagai, Masayuki, Saya, Hideyuki
Publicado 2015

Life-threatening rocuronium-induced anaphylactic shock without cutaneous manifestations successfully reversed with sugammadex: a case report

por Takise, Yoshiaki, Kato, Jungo, Suhara, Tomohiro, Yamada, Takashige, Funakoshi, Takeru, Takahashi, Hayato, Amagai, Masayuki, Morisaki, Hiroshi
Publicado 2020

Imatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy: A phase I/II trial and study protocol

por Hirai, Ikuko, Tanese, Keiji, Fukuda, Keitaro, Fusumae, Takayuki, Nakamura, Yoshio, Sato, Yasunori, Amagai, Masayuki, Funakoshi, Takeru
Publicado 2021

Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy

por Nakamura, Yoshio, Kitano, Shigehisa, Takahashi, Akira, Tsutsumida, Arata, Namikawa, Kenjiro, Tanese, Keiji, Abe, Takayuki, Funakoshi, Takeru, Yamamoto, Noboru, Amagai, Masayuki, Yamazaki, Naoya
Publicado 2016

Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors

por Fujikawa, Kaoru, Saito, Takuro, Kurose, Koji, Kojima, Takashi, Funakoshi, Takeru, Sato, Eiichi, Kakimi, Kazuhiro, Iida, Shinsuke, Doki, Yuichiro, Oka, Mikio, Ueda, Ryuzo, Wada, Hisashi
Publicado 2023

Acute onset olfactory/taste disorders are associated with a high viral burden in mild or asymptomatic SARS-CoV-2 infections

por Nakagawara, Kensuke, Masaki, Katsunori, Uwamino, Yoshifumi, Kabata, Hiroki, Uchida, Sho, Uno, Shunsuke, Asakura, Takanori, Funakoshi, Takeru, Kanzaki, Sho, Ishii, Makoto, Hasegawa, Naoki, Fukunaga, Koichi
Publicado 2020

The Entire Intestinal Tract Surveillance Using Capsule Endoscopy after Immune Checkpoint Inhibitor Administration: A Prospective Observational Study

por Shimozaki, Keitaro, Hirata, Kenro, Horie, Sara, Chida, Akihiko, Tsugaru, Kai, Hayashi, Yukie, Kawasaki, Kenta, Miyanaga, Ryoichi, Hayashi, Hideyuki, Mizuno, Ryuichi, Funakoshi, Takeru, Hosoe, Naoki, Hamamoto, Yasuo, Kanai, Takanori
Publicado 2021

Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors

por Saito, Takuro, Kurose, Koji, Kojima, Takashi, Funakoshi, Takeru, Sato, Eiichi, Nishikawa, Hiroyoshi, Nakajima, Jun, Seto, Yasuyuki, Kakimi, Kazuhiro, Iida, Shinsuke, Doki, Yuichiro, Oka, Mikio, Ueda, Ryuzo, Wada, Hisashi
Publicado 2021

Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors

por Shimozaki, Keitaro, Sukawa, Yasutaka, Beppu, Noriko, Kurihara, Isao, Suzuki, Shigeaki, Mizuno, Ryuichi, Funakoshi, Takeru, Ikemura, Shinnosuke, Tsugaru, Kai, Togasaki, Kazuhiro, Kawasaki, Kenta, Hirata, Kenro, Hayashi, Hideyuki, Hamamoto, Yasuo, Takaishi, Hiromasa, Kanai, Takanori
Publicado 2020

Variable indoleamine 2,3‐dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy

por Iga, Natsuko, Otsuka, Atsushi, Hirata, Masahiro, Kataoka, Tatsuki R., Irie, Hiroyuki, Nakashima, Chisa, Matsushita, Shigeto, Uchi, Hiroshi, Yamamoto, Yuki, Funakoshi, Takeru, Fujisawa, Yasuhiro, Yoshino, Koji, Fujimura, Taku, Hata, Hiroo, Ishida, Yoshihiro, Kabashima, Kenji
Publicado 2019

Rituximab therapy for intractable pemphigus: A multicenter, open‐label, single‐arm, prospective study of 20 Japanese patients

por Yamagami, Jun, Kurihara, Yuichi, Funakoshi, Takeru, Saito, Yasuko, Tanaka, Ryo, Takahashi, Hayato, Ujiie, Hideyuki, Iwata, Hiroaki, Hirai, Yoji, Iwatsuki, Keiji, Ishii, Norito, Sakurai, Jun, Abe, Takayuki, Takemura, Ryo, Mashino, Naomi, Abe, Masahiro, Amagai, Masayuki
Publicado 2022

Estimating copy number using next-generation sequencing to determine ERBB2 amplification status

por Nakamura, Kohei, Aimono, Eriko, Oba, Junna, Hayashi, Hideyuki, Tanishima, Shigeki, Hayashida, Tetsu, Chiyoda, Tatsuyuki, Kosaka, Takeo, Hishida, Tomoyuki, Kawakubo, Hirohumi, Kitago, Minoru, Okabayashi, Koji, Funakoshi, Takeru, Okita, Hajime, Ikeda, Sadakatsu, Takaishi, Hiromasa, Nishihara, Hiroshi
Publicado 2021

AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma

por Fukuda, Keitaro, Okamura, Ken, Riding, Rebecca L., Fan, Xueli, Afshari, Khashayar, Haddadi, Nazgol-Sadat, McCauley, Sean M., Guney, Mehmet H., Luban, Jeremy, Funakoshi, Takeru, Yaguchi, Tomonori, Kawakami, Yutaka, Khvorova, Anastasia, Fitzgerald, Katherine A., Harris, John E.
Publicado 2021

Accumulation of exhausted CD8+ T cells in extramammary Paget’s disease

por Iga, Natsuko, Otsuka, Atsushi, Yamamoto, Yosuke, Nakashima, Chisa, Honda, Tetsuya, Kitoh, Akihiko, Nakajima, Saeko, Egawa, Gyohei, Nomura, Takashi, Dainichi, Teruki, Matsushita, Shigeto, Tanizaki, Hideaki, Yamamoto, Yuki, Funakoshi, Takeru, Fujisawa, Yasuhiro, Fujimura, Taku, Hata, Hiroo, Ishida, Yoshihiro, Kabashima, Kenji
Publicado 2019

Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study)

por Ishii, Maki, Hirai, Ikuko, Tanese, Keiji, Fusumae, Takayuki, Nakamura, Yoshio, Fukuda, Keitaro, Uchi, Hiroshi, Kabashima, Kenji, Otsuka, Atsushi, Yokota, Kenji, Yamazaki, Naoya, Namikawa, Kenjiro, Fujimura, Taku, Takenouchi, Tatsuya, Yamamoto, Yuki, Nishiguchi, Mana, Sato, Yasunori, Amagai, Masayuki, Funakoshi, Takeru
Publicado 2020

Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study

por Fujimura, Taku, Sato, Yota, Tanita, Kayo, Kambayashi, Yumi, Otsuka, Atsushi, Fujisawa, Yasuhiro, Yoshino, Koji, Matsushita, Shigeto, Funakoshi, Takeru, Hata, Hiroo, Yamamoto, Yuki, Uchi, Hiroshi, Nonomura, Yumi, Tanaka, Ryota, Aoki, Megumi, Imafuku, Keisuke, Okuhira, Hisako, Furudate, Sadanori, Hidaka, Takanori, Aiba, Setsuya
Publicado 2018